14.06.2024  17:30:06 Изменение -0.0010 Объем сделки Бид17:40:00 Предложение17:40:00 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
0.0650CHF -1.52% 34,021
Оборот: 2,179.4060
0.0600Величина цены спроса: 44,246 0.0660Величина цены предложения: 1,000 11.59 млнCHF - -

Описание деятельности

Addex Therapeutics (formerly Addex Pharmaceuticals Ltd.) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, mGluR3PAM and TrkBPAM.
 

Правление & Наблюдательный совет

Исполнительный директор
Tim Dyer
Правление
Jean-Philippe Rocher, Mikhail Kalinichev, Robert Lütjens, Roger G. Mills
Наблюдательный совет
Issac Manke, Jake Nunn, Raymond Hill, Vincent Lawton
 

Данные компании

Имя: Addex Therapeutics Ltd
Адрес: 12 Chemin des Aulx,CH-1228 Plan-les-Ouates / Geneva
Телефон: +41-22-884-1555
Факс: +41-22-884-1556
E-mail: info@addextherapeutics.com
Интернет: www.addextherapeutics.com
Индустрия: Healthcare
Сектор: Medical Products
Подсектор: Advanced Medical Devices
Конец финансового года: 31.12
Акции в свободном обращении: 38.48%
Дата IPO: 22.05.2007

Связи с инвесторами

Имя: -
IR телефон: +41-22-884-1555
IR-факс: +41 22 884 1556
IR e-mail: investor.relations@a...ics.com investor.relations@addextherapeutics.com

Основные акционеры

Другие
 
59.52%
Addex Pharma SA
 
33.19%
Tim Dyer
 
4.12%
Growth Equity Opportunities Fund IV
 
3.17%